Brokerages Set MDxHealth SA (NASDAQ:MDXH) Price Target at $4.62

Shares of MDxHealth SA (NASDAQ:MDXH) have received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $4.6250.

MDXH has been the topic of several analyst reports. Wall Street Zen downgraded shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. TD Cowen reaffirmed a “buy” rating and issued a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday, May 14th. William Blair downgraded MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. BTIG Research lowered their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, Lake Street Capital cut their price objective on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th.

MDxHealth Stock Performance

Shares of MDXH opened at $0.48 on Friday. The firm has a market cap of $23.59 million, a PE ratio of -0.73 and a beta of 1.43. The firm’s 50 day moving average price is $1.02 and its 200 day moving average price is $2.43. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $23.90 million for the quarter, compared to the consensus estimate of $30.89 million. On average, sell-side analysts anticipate that MDxHealth will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

A number of hedge funds have recently bought and sold shares of the company. Intesa Sanpaolo Wealth Management acquired a new stake in shares of MDxHealth in the fourth quarter valued at about $36,000. Lido Advisors LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth about $48,000. GSA Capital Partners LLP bought a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new stake in MDxHealth during the 4th quarter valued at approximately $51,000. Finally, Jefferies Financial Group Inc. acquired a new stake in MDxHealth in the 3rd quarter valued at approximately $53,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.